Equities research analysts expect Zoetis Inc (NYSE:ZTS) to post $0.65 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Zoetis’ earnings, with estimates ranging from $0.59 to $0.69. Zoetis reported earnings per share of $0.90 in the same quarter last year, which would indicate a negative year-over-year growth rate of 27.8%. The firm is expected to report its next quarterly earnings results on Tuesday, August 4th.

On average, analysts expect that Zoetis will report full year earnings of $3.37 per share for the current year, with EPS estimates ranging from $3.17 to $3.90. For the next financial year, analysts anticipate that the company will post earnings of $4.05 per share, with EPS estimates ranging from $3.87 to $4.45. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Zoetis.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.95 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.86 by $0.09. Zoetis had a net margin of 25.41% and a return on equity of 67.72%. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.50 billion. During the same period in the prior year, the company posted $0.88 EPS. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis.

ZTS has been the topic of a number of recent analyst reports. Cfra raised shares of Zoetis from a “buy” rating to a “strong-buy” rating and increased their price objective for the stock from $147.00 to $160.00 in a research report on Thursday, February 13th. Bank of America restated a “hold” rating and issued a $145.00 target price on shares of Zoetis in a research note on Wednesday, February 12th. UBS Group dropped their target price on shares of Zoetis from $146.00 to $126.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. SunTrust Banks restated a “hold” rating and issued a $145.00 target price on shares of Zoetis in a research note on Friday, February 14th. Finally, G.Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Tuesday, March 31st. Seven equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $138.40.

Zoetis stock opened at $127.49 on Thursday. The company has a debt-to-equity ratio of 2.22, a current ratio of 2.77 and a quick ratio of 1.91. Zoetis has a 1-year low of $90.14 and a 1-year high of $146.26. The firm has a market capitalization of $59.59 billion, a P/E ratio of 38.06, a price-to-earnings-growth ratio of 4.48 and a beta of 0.78. The company’s 50-day moving average is $123.39 and its 200 day moving average is $127.88.

In other Zoetis news, Director Juan Ramon Alaix sold 63,046 shares of the firm’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $144.03, for a total value of $9,080,515.38. Following the completion of the sale, the director now directly owns 159,059 shares in the company, valued at $22,909,267.77. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Kristin C. Peck sold 11,925 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $138.10, for a total transaction of $1,646,842.50. Following the completion of the sale, the chief executive officer now owns 51,799 shares of the company’s stock, valued at $7,153,441.90. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 125,427 shares of company stock valued at $17,760,362. 0.17% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Peapack Gladstone Financial Corp boosted its stake in Zoetis by 4.7% in the first quarter. Peapack Gladstone Financial Corp now owns 3,776 shares of the company’s stock valued at $445,000 after acquiring an additional 170 shares in the last quarter. Capital Research Global Investors raised its holdings in shares of Zoetis by 66.2% in the first quarter. Capital Research Global Investors now owns 3,627,340 shares of the company’s stock worth $426,902,000 after buying an additional 1,444,228 shares during the last quarter. Exencial Wealth Advisors LLC raised its holdings in shares of Zoetis by 3.9% in the first quarter. Exencial Wealth Advisors LLC now owns 55,137 shares of the company’s stock worth $6,489,000 after buying an additional 2,077 shares during the last quarter. Forbes J M & Co. LLP raised its holdings in shares of Zoetis by 5.7% in the first quarter. Forbes J M & Co. LLP now owns 163,443 shares of the company’s stock worth $19,236,000 after buying an additional 8,854 shares during the last quarter. Finally, Engineers Gate Manager LP raised its holdings in shares of Zoetis by 27.8% in the first quarter. Engineers Gate Manager LP now owns 5,278 shares of the company’s stock worth $621,000 after buying an additional 1,148 shares during the last quarter. Institutional investors own 91.85% of the company’s stock.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Further Reading: Total Return

Get a free copy of the Zacks research report on Zoetis (ZTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.